Saturday 17 October 2026
Export RVLP’s income statement to Excel — free account
RVL Pharmaceuticals PLC
RVLP Healthcare Biotechnology
RVL Pharmaceuticals PLC’s revenue for fiscal 2022 (year ended December 2022) was $49.7 million.
Follow RVLP
| Jun '23 | Mar '23 | Dec '22 | Sep '22 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 3 | 4 |
+8 more TTM periods Free account |
| (182.44%) | (103.18%) | (80.88%) | (86.13%) | ||
| (64.94%) | (44.23%) | (37.84%) | (40.09%) | ||
ROIC |
(80.54%) | (61.84%) | (58.06%) | (55.09%) | |
Return on Tangible Assets |
174.15% | (231.19%) | (134.17%) | (105.97%) | |
Average Days of Receivables |
19.10 | 18.48 | 22.25 | 27.99 | |
Free Cash Flow per Share |
(0.48) | (0.33) | (0.43) | (0.49) | |
Free Cash Flow |
(47.41) | (32.34) | (38.56) | (45.64) | |
Capital Expenditures |
(3.00) | (1.99) | (0.75) | 0.13 | |
| Other line items | |||||
Cash ROIC |
(50.85%) | (24.91%) | (25.27%) | (24.70%) | |
Accounts Receivable Turnover |
19.61 | 3.82 | 19.26 | 11.45 | |
Accounts Payable Turnover |
2.34 | 2.61 | 3.06 | 1.39 | |
Inventory Turnover |
9.90 | 18.29 | 11.66 | 11.04 | |
Average Days of Payables |
98.98 | 99.88 | 92.91 | 320.35 | |
Days of Inventory on Hand |
53.05 | 8.09 | 30.26 | 28.41 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.40% | 10.05% | 7.98% | 9.87% | |
Selling, General and Administrative Expense of Revenue |
184.35% | 200.34% | 164.88% | 205.90% | |
Share Based Compensation of Revenue |
6.45% | 9.05% | 8.19% | 9.77% | |
Interest Coverage |
(59.68) | (14.85) | (9.48) | (6.56) | |
Operating CF/Net income |
0.65 | 0.54 | 0.73 | 0.86 | |
Depreciation/Fixed assets |
8.91 | 6.35 | 13.13 | 2.94 | |
Capex/Depreciation |
(0.10) | (0.13) | (0.04) | 0.07 | |
Revenue per Share |
0.37 | 0.37 | 0.55 | 0.46 | |
Operating CF per Share |
(0.45) | (0.31) | (0.42) | (0.49) | |
Capex per Share |
(0.03) | (0.02) | (0.01) | 0.00 | |
Capex to Sales |
0.08 | 0.05 | 0.02 | 0.00 |
Columns are period end dates